SOLIDUS INVESTMENT

SOLIDUS INVESTMENT (Korean: (주)솔리더스인베스트먼트) is a South Korean venture capital and private equity firm headquartered in Gangnam-gu, Seoul. It was established in June 2011 and registered as a venture investment company with the Small and Medium Business Administration in July of the same year. The firm focuses primarily on the pharmaceutical, bio and healthcare sectors, acting as a value-creating partner for venture and small-to-medium enterprises. According to its official history, it formed its first fund in December 2011, the Solidus Global Agri-Food Bio Investment Fund No. 1, with 17 billion won in committed capital. Over the following decade, SOLIDUS built a series of specialized funds. In 2013 it formed the Solidus-Gochang Agri-Food Project Investment Fund (10 billion won) and the Mirae Creation IBKC-Solidus Bio Secondary Investment Fund (30 billion won). In 2014 it formed the 2014 Solidus Growth Ladder Startup Fund (20 billion won) and moved offices. In 2016 it launched the KB-Solidus Global Healthcare Fund with 150 billion won. In 2021 it formed the Solidus Smart Bio Investment Fund (100 billion won) and Solidus Star Venture Investment Fund No. 1 (5 billion won). In 2022 it formed the KB-Solidus Healthcare Investment Fund (102 billion won). In 2023 it formed the IBK-Solidus Next Bio Star Investment Fund (23.5 billion won) and the Solidus Star Venture Investment Fund No. 2 (4.05 billion won). In 2025 it formed the IBKC-Solidus Smart Bio Investment Fund No. 2 (80 billion won). According to Korean Wikipedia, SOLIDUS INVESTMENT is a venture capital/private equity firm affiliated with the Cha Bio Group, investing mainly in pharmaceuticals, bio and healthcare. As of 2025 its assets under management were approximately 481.6 billion won, and by November 2023 it had deployed about 228 billion won into 55 bio companies. Notable portfolio companies include Genomictree, Alteogen (100 billion won invested), Geninus, Kanaph Therapeutics, IMBiologics, Ubix Therapeutics, Arribio and CapsBio. The firm's official website also presents it as part of the JW Group family, with pages dedicated to JW Promise and JW WAY, the JW Group's management philosophy and working principles. In 2026, according to the official history page, there was a change of largest shareholder to JW Holdings, and the KB-Solidus Global Healthcare Fund was liquidated with an IRR of 12.31% and a multiple of 1.65x. Korean Wikipedia notes that in November 2025 a sale process was underway and Dongkuk Pharmaceutical was reviewing an acquisition of the company. SOLIDUS INVESTMENT remains active as a specialized healthcare and bio investor in South Korea.

SOLIDUS INVESTMENT was established in June 2011 as (주)솔리더스인베스트먼트 and registered as a venture investment company with the Small and Medium Business Administration in July 2011. In December 2011, it formed its first fund, the Solidus Global Agri-Food Bio Investment Fund No. 1, with 170 billion won in committed capital. In May 2012, the CEO changed from Yoon Woong-jin to Kim Jeong-hyun. In June 2013, the company increased its capital from 5 billion won to 8 billion won. In July 2013, it formed the Solidus-Gochang Agri-Food Project Investment Fund (10 billion won), and in December 2013, the Mirae Creation IBKC-Solidus Bio Secondary Investment Fund (30 billion won). In September 2014, the office was relocated, and in January 2015, the 2014 Solidus Growth Ladder Startup Fund was formed with 20 billion won. In January 2016, the KB-Solidus Global Healthcare Fund was formed with 150 billion won. In July 2018, the Solidus Global Agri-Food Bio Investment Fund No. 1 was liquidated with an IRR of 17% and a multiple of 2.24x. In January 2021, the Solidus Star Venture Investment Fund No. 1 (5 billion won) was formed, and in March 2021, the Solidus Smart Bio Investment Fund (100 billion won) was formed. In January 2022, the KB-Solidus Healthcare Investment Fund was formed with 102 billion won. In 2023, the IBK-Solidus Next Bio Star Investment Fund (23.5 billion won) was formed in March; the Solidus-Gochang Agri-Food Project Investment Fund was liquidated in June; the Mirae Creation IBKC-Solidus Bio Secondary Investment Fund was liquidated in June with an IRR of 14.8% and a multiple of 1.9x; and the Solidus Star Venture Investment Fund No. 2 (4.05 billion won) was formed in October. In 2025, the IBKC-Solidus Smart Bio Investment Fund No. 2 was formed with 80 billion won. In 2026, according to the official history, the largest shareholder changed to JW Holdings, and the KB-Solidus Global Healthcare Fund was liquidated with an IRR of 12.31% and a multiple of 1.65x. Korean Wikipedia notes that in 2023 the company signed an MOU with Chungnam National University and its technology holding company; in 2024 it was selected alongside IBK Capital as a manager of a 100 billion won K-Bio and vaccine fund; and in 2025 it applied for a 20 billion won bio fund mandate from the Science and Technology Personnel Mutual Aid Association (KOFAC). As of November 2025, a sale process was underway, with Dongkuk Pharmaceutical reviewing an acquisition. As of 2025, AUM was approximately 481.6 billion won, and by November 2023 it had invested about 228 billion won in 55 bio companies.

• Company established as (주)솔리더스인베스트먼트

• Registered as a venture investment company with the Small and Medium Business Administration

• Solidus Global Agri-Food Bio Investment Fund No. 1 formed (17 billion won)

• CEO changed from Yoon Woong-jin to Kim Jeong-hyun

• Capital increased from 5 billion won to 8 billion won

• Solidus-Gochang Agri-Food Project Investment Fund formed (10 billion won)

• Mirae Creation IBKC-Solidus Bio Secondary Investment Fund formed (30 billion won)

• Office relocated

• 2014 Solidus Growth Ladder Startup Fund formed (20 billion won)

• KB-Solidus Global Healthcare Fund formed (150 billion won)

• Solidus Global Agri-Food Bio Investment Fund No. 1 liquidated (IRR 17%, Multiple 2.24x)

• Solidus Star Venture Investment Fund No. 1 formed (5 billion won)

• Solidus Smart Bio Investment Fund formed (100 billion won)

• KB-Solidus Healthcare Investment Fund formed (102 billion won)

• IBK-Solidus Next Bio Star Investment Fund formed (23.5 billion won)

• Solidus-Gochang Agri-Food Project Investment Fund liquidated

• Mirae Creation IBKC-Solidus Bio Secondary Investment Fund liquidated (IRR 14.8%, Multiple 1.9x)

• Solidus Star Venture Investment Fund No. 2 formed (4.05 billion won)

• MOU signed with Chungnam National University and its technology holding company

• Selected as manager of 100 billion won K-Bio/Vaccine Fund alongside IBK Capital

• IBKC-Solidus Smart Bio Investment Fund No. 2 formed (80 billion won)

• Applied for 20 billion won bio fund mandate from KOFAC

• Sale process underway; Dongkuk Pharmaceutical reviewing acquisition

• Largest shareholder changed to JW Holdings; KB-Solidus Global Healthcare Fund liquidated (IRR 12.31%, Multiple 1.65x)

A specialized venture capital and private equity firm focused on bio, healthcare and pharmaceutical investments, operating as a value-creating partner for ventures and SMEs within the JW Group.

• Solidus Global Agri-Food Bio Investment Fund No. 1

  First fund formed in 2011 with 17 billion won; liquidated in 2018 with IRR 17% and multiple 2.24x.

• Solidus-Gochang Agri-Food Project Investment Fund

  Formed in 2013 with 10 billion won; liquidated in 2023.

• Mirae Creation IBKC-Solidus Bio Secondary Investment Fund

  Formed in 2013 with 30 billion won; liquidated in 2023 with IRR 14.8% and multiple 1.9x.

• 2014 Solidus Growth Ladder Startup Fund

  Formed in 2015 with 20 billion won.

• KB-Solidus Global Healthcare Fund

  Formed in 2016 with 150 billion won; liquidated in 2026 with IRR 12.31% and multiple 1.65x.

• Solidus Star Venture Investment Fund No. 1

  Formed in 2021 with 5 billion won.

• Solidus Smart Bio Investment Fund

  Formed in 2021 with 100 billion won.

• KB-Solidus Healthcare Investment Fund

  Formed in 2022 with 102 billion won.

• IBK-Solidus Next Bio Star Investment Fund

  Formed in 2023 with 23.5 billion won.

• Solidus Star Venture Investment Fund No. 2

  Formed in 2023 with 4.05 billion won.

• IBKC-Solidus Smart Bio Investment Fund No. 2

  Formed in 2025 with 80 billion won.

1. 1:: SOLIDUS ::solidusvc.com
2. 2:: SOLIDUS :: Historysolidusvc.com
3. 3:: SOLIDUS :: JW WAYsolidusvc.com
4. 4:: SOLIDUS :: JW Promisesolidusvc.com
5. 5Wikidata Q137710915wikidata.org
6. 6솔리더스인베스트먼트 - Wikipediako.wikipedia.org